Recent advances on the immunomodulatory effects of IFN-α: Implications for cancer immunotherapy and autoimmunity

References

• Vilcek J. Fifty years of interferon research: Aiming at a moving target. Immunity. 2006; 25:343–348.
   PubMed Web of Science ®Google Scholar
• Mogensen KE, Lewerenz M, Reboul J, Lutfalla G, Uze G. Type I IFN receptor: Structure, function, and evolution of a family business. J Interferon Cytokine Res. 1999; 19:1069–1098.
   PubMed Web of Science ®Google Scholar
• Gutterman JU. Cytokine therapeutics: Lessons from interferon-alpha. Proc Natl Acad Sci USA. 1994; 91:1198–1205.
   PubMed Web of Science ®Google Scholar
• Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol Today. 1996; 17:369–372.
   PubMedGoogle Scholar
• Gresser I. The antitumor effects of interferon: A personal history. Biochimie. 2007; 89:723–728.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Belardelli F. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 2002; 23:201–208.
   Google Scholar
• Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-scid mice. J Exp Med. 2000; 191:1777–1788.
   PubMed Web of Science ®Google Scholar
• Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007; 19:61–66.
   Web of Science ®Google Scholar
• Gresser I. Can interferon induce disease?. Interferon. 1982; 4:95–127.
   Google Scholar
• Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol. 2007; 316:359–386.
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001; 294:1540–1543.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I IFN in systemic lupus erythematosus and other autoimmune diseases. Immunity. 2006; 25:383–392.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Belardelli F. Gene therapy of cancer with interferon: Lessons from tumor models and perspectives for clinical applications. Semin Cancer Biol. 2000; 10:145–157.
   PubMed Web of Science ®Google Scholar
• Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13:119–134.
   PubMed Web of Science ®Google Scholar
• Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: Mechanisms of action and new perspectives of clinical use. Biochimie. 2007; 89:884–893.
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006; 354:709–718.
   PubMed Web of Science ®Google Scholar
• Koon H, Atkins M. Autoimmunity and immunotherapy of cancer. New Engl J Med. 2006; 354:758–760.
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F, Patuzzo R, Pennacchioli E, Santinami M, Cova A, Sovena G, Arienti F, Lombardo C, Lombardi A, Caporaso P, D'Atri S, Marchetti P, Bonmassar E, Parmiani G, Belardelli F, Rivoltini L. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-α results in the activation of specific CD8+ T cells and monocyte/dendritic cell precursors. Cancer Res. 2006; 66:4943–4951.
   PubMed Web of Science ®Google Scholar
• Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001; 14:461–470.
   PubMed Web of Science ®Google Scholar
• Proietti E, Bracci L, Puzelli S, Di Pucchio T, Sestili P, De Vincenzi E, Venditti M, Capone I, Seif I, De Maeyer E, Tough D, Donatelli I, Belardelli F. Type I IFN as a natural adjuvant for a protective immune response: Lessons from the influenza vaccine model. J Immunol. 2002; 169:375–383.
   PubMed Web of Science ®Google Scholar
• Rizza P, Capone I, Urbani F, Montefiore E, Rapicetta M, Chionne P, Candido A, Tosti ME, Grimaldi M, Palazzini E, Viscomi G, Cursaro C, Margotti M, Scuteri A, Andreone P, Taylor E, Haygreen EA, Tough DF, Borrow P, Selleri M, Castilletti C, Capobianchi M, Belardelli F. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine. 2008; 26:1038–1049.
   PubMed Web of Science ®Google Scholar
• Nisticò P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, Aricò E, Valentini M, Bracci L, Cognetti F, Ciccarese M, Vercillo G, Roselli M, Fossile E, Tosti ME, Wang E, Marincola F, Imberti L, Catricalà C, Natali PG, Belardelli F, Proietti E. Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer. 2009; 124:1309.
   Google Scholar
• Romagnani S. Induction of TH1 and TH2 responses: A key role for the ‘natural’ immune response?. Immunol Today. 1992; 13:379–381.
   PubMedGoogle Scholar
• Palmer KJ, Harries M, Gore ME, Collins MK. Interpheron-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumor cultures (MLTC). Clin Exp Immunol. 2000; 119:412–418.
   PubMed Web of Science ®Google Scholar
• Tough DF, Borrow P, Sprent J. Induction of bystander T-cell proliferation by viruses and type I interferon in vivo. Science. 1996; 272:1947–1950.
   PubMed Web of Science ®Google Scholar
• Sun S, Zhang X, Tough DF, Sprent J. Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998; 188:2335–2342.
   PubMed Web of Science ®Google Scholar
• Marrack P, Kappler J, Mitchell T. Type I interferons keep activated T cells alive. J Exp Med. 1999; 189:521–530.
   PubMed Web of Science ®Google Scholar
• Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999; 93:1980–1991.
   PubMed Web of Science ®Google Scholar
• Santini SM, Di Pucchio T, Lapenta C, Logozzi M, Parlato S, Belardelli F. The natural alliance between type I IFN and dendritic cells and its role in linking innate and adaptive immunity. J Interferon Cytokine Res. 2002; 22:1071–1080.
   PubMedGoogle Scholar
• Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F. A new type I IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells. 2003; 21:357–362.
   Google Scholar
• Cella M, Sallusto F, Lanzavecchia A. Origin, maturation, and antigen-presenting function of dendritic cells. Curr Opin Immunol. 1997; 9:10–16.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007; 449:419–426.
   PubMed Web of Science ®Google Scholar
• Belardelli F, Ferrantini M, Parmiani G, Schlom J, Garaci E. International meeting on cancer vaccines: How can we enhance efficacy of therapeutic vaccines?. Cancer Res. 2004; 64:6827–6830.
   PubMedGoogle Scholar
• Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998; 64:358–367.
   PubMed Web of Science ®Google Scholar
• Luft T, Pang KC, Thomas E, Hertzog P, Hart DN, Trapani J, Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998; 161:1947–1953.
   PubMed Web of Science ®Google Scholar
• Radvanyi LG, Banerjee A, Weir M, Messner H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. Scand J Immunol. 1999; 50:499–500.
   PubMed Web of Science ®Google Scholar
• Santodonato L, D'Agostino G, Nisini R, Mariotti S, Monque DM, Spada M, Lattanzi L, Perrone MP, Andreotti M, Belardelli F, Ferrantini M. Monocyte-derived dendritic cells generated after a short-term culture with IFN-α and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T-cell response. J Immunol. 2003; 170:5195–5202.
   PubMed Web of Science ®Google Scholar
• Lapenta C, Santini SM, Logozzi M, Spada M, Andreotti M, Di Pucchio T, Parlato S, Belardelli F. Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated-virus-pulsed dendritic cells generated in the presence of IFN-α. J Exp Med. 2003; 198:361–367.
   PubMed Web of Science ®Google Scholar
• Tosi D, Valenti R, Cova A, Sovena G, Huber V, Pilla L, Arienti F, Belardelli F, Parmiani G, Rivoltini L. Role of cross-talk between IFN-α-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T-cell responses against human tumor antigens. J Immunol. 2004; 172:5363–5370.
   PubMed Web of Science ®Google Scholar
• Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F. IFN-α-conditioned dendritic cells are highly efficient in inducing cross-priming CD8+ T-cells against exogenous viral antigens even in the absence of CD4+ T-cell help. Eur J Immunol. 2006; 36:2046–2060.
   PubMed Web of Science ®Google Scholar
• Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foà R, Belardelli F. IFN-α promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood. 2004; 103:980–987.
   PubMed Web of Science ®Google Scholar
• Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998; 392:386–389.
   Google Scholar
• Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol. 1999; 17:529–533.
   PubMed Web of Science ®Google Scholar
• Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23:741–750.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298:850–854.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med. 2003; 198:569–580.
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999; 190:355–366.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: Targeting the “self” to destroy the “other”. Crit Rev Immunol. 2000; 20:433–450.
   PubMed Web of Science ®Google Scholar